HBIO HARVARD BIOSCIENCE INC Insider Trading

CFO Mark T Frost buys 5,000 shares of HBIO at $5.00; holdings now 17.5K shares (+40.0%)

Frost acquired 5,000 shares at $5.00 on 2026-03-16, increasing his stake from 12,500 to 17.5K shares. The company currently trades at $5.09, only 1.8% above the purchase price, and is -35.3% from its 52-week high of $7.87. More pressingly, the company reported a net loss of $-1.2M in its latest quarter and remains unprofitable on a full-year basis, with annual revenue declining -8.1% year-over-year. The CFO's 40.0% increase in personal holdings occurs in a deteriorating operational backdrop—declining revenues, negative earnings, and a stock down 13.9% over the past 30 days. The proximity of the purchase price to current market price and the company's negative fundamentals limit the bullish signal normally associated with insider accumulation.

Director Snider William bought 21,000 shares (21.0K shares) for $103,603.50 across 2 trades; cluster pattern: 3 other insiders also bought within 14 days.

Director William Snider purchased 21,000 shares (21.0K shares) across two transactions on 2026-03-16 and 2026-03-17 at an blended average price of $4.93, increasing his holdings by 190.9% from 11,000 shares to 32,000 shares post-transaction. This filing is part of a cluster buy pattern with 3 other insiders also purchasing within the past 14 days, suggesting coordinated accumulation at the director level. The buys occurred near the lower end of the 52-week range ($2.84–$7.87) and amid a -36.4% decline over the past 90 days, though they were executed at prices ($4.99 and $4.85) slightly above the current price of $4.88. Harvard Bioscience remains unprofitable with a net income of $-1.2M in the latest quarter, annual revenue declining -8.1% year-over-year, and a market cap of $218.2M, indicating that multiple insiders are accumulating shares in a distressed operational environment.

Director Denelsky bought 10,000 HBIO shares at $4.87; 3 other insiders also bought within 14 days amid -8.1% revenue decline and unprofitability.

Director Stephen J Denelsky purchased 10,000 shares at $4.87 on 2026-03-17, doubling his position from 11,000 to 21,000 shares. The stock has declined 12.0% over 30 days and 36.4% over 90 days from its 52-week high of $7.87, trading at $4.88 (current). The company reports revenue of $20.6M in the latest quarter but is unprofitable with a net income of $-1.2M and faces an 8.1% annual revenue decline. Critically, a cluster buy pattern emerges: 3 other insiders purchased shares within the same 14-day window. This coordinated accumulation by multiple board-level insiders during a period of declining financial performance and depressed stock price warrants investigation into management's assessment of valuation and forward-looking catalysts.

CEO Duke John D buys 5,000 shares at $5.01; stock down 38.1% from 52-week high as company posts negative earnings.

Duke John D, Chief Executive Officer, purchased 5,000 shares at $5.01 on 2026-03-16, increasing his holdings from 100,000 to 105,000 shares. The purchase occurs with the stock trading at $4.87, down 38.1% from its 52-week high of $7.87 and down 12.2% over the past 30 days. Notably, 3 other insiders also bought within the past 14 days, establishing a cluster buy pattern. The company's fundamentals remain challenged: latest quarterly revenue was $20.6M, net income was $-1.2M, annual revenue contracted 8.1%, and the company was unprofitable over its most recent full fiscal year. The confluence of multiple insiders acquiring at depressed price levels while the business remains unprofitable and declining warrants close investor attention.

CEO Green James W bought 10,000 HBIO shares at $2.91 on 2024-06-13; stock down 52.3% from 52-week high, trading near lows.

CEO James W Green purchased 10,000 shares at $2.91 on 2024-06-13, increasing holdings to 3,111,091 shares. The purchase occurs as HBIO trades at $28.95, down 52.3% from its 52-week high of $60.70 and down 16.1% over 30 days, reflecting significant recent weakness. Green has demonstrated a strong historical pattern across his prior open-market trades: his cross-ticker track record shows 2 prior buys with average 90-day returns of +870.3% and a 100% win rate, and his prior buy at HBIO on 2023-08-17 returned +870.3% over 90 days. However, the company's fundamentals present a countervailing signal: HBIO reported $24,512,000 in latest quarterly revenue with a $-4,694,000 net loss, and annual revenue growth was negative at -1.0%, with the company unprofitable over its most recent full fiscal year. The combination of a historically successful insider accumulating shares during a period of steep price decline against a backdrop of negative earnings and flat revenue growth warrants deeper analysis of the company's path to profitability.